MedTrace Logo

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

NCT00872950 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2022-04-11

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).

Conditions

  • Lambert-Eaton Myasthenic Syndrome
  • Congenital Myasthenic Syndrome

Interventions

DRUG

3,4-DIAMINOPYRIDINE

Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.

Sponsors & Collaborators

  • Lahey Clinic

    lead OTHER

Principal Investigators

  • Jayashri Srinivasan, MD,MCRP,PhD · Lahey Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00872950 on ClinicalTrials.gov